Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer

Extrachromosomal DNA (ecDNA) has emerged as a major contributor to cancer aggressiveness, yet its role extends far beyond its classical definition as a vehicle for oncogene amplification. Recent studies indicate that ecDNA functions as a dynamic regulatory platform that reshapes chromatin accessibility, enhancer activity, three-dimensional genome organization, nuclear architecture, and transcriptional output. Through these properties, ecDNA enables cancer cells to amplify oncogenic signaling, generate transcriptional plasticity, and rapidly adapt to selective pressures. In contrast to chromosomal amplification, ecDNA is structurally independent, frequently circular, acentromeric, and inherited through noncanonical mitotic behaviors, allowing unequal segregation, coordinated co-inheritance, and persistent propagation of advantageous regulatory states. Emerging evidence further shows that ecDNA can hijack pre-existing enhancers, rewire enhancer–oncogene communication, activate noncanonical regulatory elements, and assemble into transcriptionally active nuclear hubs and condensate-associated structures, thereby transforming genome rearrangement into epigenetic innovation. These mechanisms position ecDNA as a key driver of intratumoral heterogeneity, clonal evolution, metastatic adaptation, and therapeutic resistance. At the same time, the high transcriptional burden and specialized regulatory architecture of ecDNA-positive tumors may create selective vulnerabilities, including transcription–replication conflict and dependence on ecDNA-associated hubs, condensates, and regulatory modules. In this review, we synthesize current advances in the formation, regulation, inheritance, and functional consequences of ecDNA, with a particular focus on its emerging role as a platform for epigenetic reprogramming in cancer. We also discuss how this conceptual shift from copy-number biology to regulatory biology may redefine ecDNA as both a mechanistic framework for tumor plasticity and a potential frontier for precision oncology. ecDNA functions as more than an amplification vehicle and acts as a dynamic platform for epigenetic reprogramming in cancer. ecDNA reshapes oncogenic regulation through open chromatin states, enhancer rewiring, noncanonical regulatory activation, and nuclear hub formation. Noncanonical inheritance and spatially organized ecDNA assemblies drive intratumoral heterogeneity, clonal evolution, and therapeutic adaptation. ecDNA-associated transcriptional stress and regulatory architecture may expose new vulnerabilities for precision cancer therapy.

Authors

Institutions

Publication Details

Journal
Molecular Cancer
Published
2026-09-17
DOI
https://doi.org/10.1186/s12943-026-02789-1
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer

Lisha Zha, Xi‐jian Dai, Bixia Liu, Jialiang Wei et al.
Molecular Cancer
Epigenetics and DNA Methylation
article

Extrachromosomal DNA as a platform for epigenetic reprogramming in cancer

Lisha Zha, Xi‐jian Dai, Bixia Liu, Jialiang Wei, Wenhan Zu, Xueqiong Han, Lei Jiang, Rui Liu, Hongkang Hu, Yuxin Wang, Shuzhen Lai, Daosong Chen, Lu Zhou, Jin Chang
article en

Abstract

Extrachromosomal DNA (ecDNA) has emerged as a major contributor to cancer aggressiveness, yet its role extends far beyond its classical definition as a vehicle for oncogene amplification. Recent studies indicate that ecDNA functions as a dynamic regulatory platform that reshapes chromatin accessibility, enhancer activity, three-dimensional genome organization, nuclear architecture, and transcriptional output. Through these properties, ecDNA enables cancer cells to amplify oncogenic signaling, generate transcriptional plasticity, and rapidly adapt to selective pressures. In contrast to chromosomal amplification, ecDNA is structurally independent, frequently circular, acentromeric, and inherited through noncanonical mitotic behaviors, allowing unequal segregation, coordinated co-inheritance, and persistent propagation of advantageous regulatory states. Emerging evidence further shows that ecDNA can hijack pre-existing enhancers, rewire enhancer–oncogene communication, activate noncanonical regulatory elements, and assemble into transcriptionally active nuclear hubs and condensate-associated structures, thereby transforming genome rearrangement into epigenetic innovation. These mechanisms position ecDNA as a key driver of intratumoral heterogeneity, clonal evolution, metastatic adaptation, and therapeutic resistance. At the same time, the high transcriptional burden and specialized regulatory architecture of ecDNA-positive tumors may create selective vulnerabilities, including transcription–replication conflict and dependence on ecDNA-associated hubs, condensates, and regulatory modules. In this review, we synthesize current advances in the formation, regulation, inheritance, and functional consequences of ecDNA, with a particular focus on its emerging role as a platform for epigenetic reprogramming in cancer. We also discuss how this conceptual shift from copy-number biology to regulatory biology may redefine ecDNA as both a mechanistic framework for tumor plasticity and a potential frontier for precision oncology. ecDNA functions as more than an amplification vehicle and acts as a dynamic platform for epigenetic reprogramming in cancer. ecDNA reshapes oncogenic regulation through open chromatin states, enhancer rewiring, noncanonical regulatory activation, and nuclear hub formation. Noncanonical inheritance and spatially organized ecDNA assemblies drive intratumoral heterogeneity, clonal evolution, and therapeutic adaptation. ecDNA-associated transcriptional stress and regulatory architecture may expose new vulnerabilities for precision cancer therapy.

Molecular Cancer
Nanchang University (CN), Guangxi University (CN), Hunan University (CN), Shantou University (CN), Shanghai Changzheng Hospital (CN), Affiliated Hospital of Taishan Medical University (CN), Second Affiliated Hospital of Nanchang University (CN), Yue Bei People's Hospital (CN), Guangxi University of Chinese Medicine (CN), First Affiliated Hospital of GuangXi Medical University (CN), First Affiliated Hospital of Gannan Medical University (CN), Shandong First Medical University (CN), South University (US)
Industry, innovation and infrastructure
Openalex Percentile: Top 19%
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.